Rituximab Role in MG Crisis
Rituximab should be considered as a rescue therapy for myasthenia gravis crisis (Grade 3-4 MG) when patients are refractory to first-line treatments (IVIG or plasmapheresis) and corticosteroids. 1
Evidence-Based Management Algorithm
When to Use Rituximab in MG Crisis
The 2021 ASCO guideline for immune-related adverse events provides the clearest framework for rituximab use in severe MG 1:
For Grade 3-4 MG (myasthenic crisis):
- Limiting self-care, weakness limiting walking, ANY dysphagia, facial weakness, respiratory muscle weakness, or rapidly progressive symptoms
- MGFA severity class III-V (moderate to severe generalized weakness to myasthenic crisis)
Treatment sequence:
- First-line: IVIG 2 g/kg IV over 5 days (0.4 g/kg/day) OR plasmapheresis 3-5 days, plus corticosteroids
- Second-line (if refractory): Add rituximab 1
Dosing Regimens
Two established dosing approaches exist 2:
- 375 mg/m² weekly for 4 weeks (FDA-approved lymphoma dosing)
- 1000 mg on days 1 and 15 (two doses, 2 weeks apart)
Both regimens appear clinically equivalent in autoimmune conditions 3, 4. The two-dose regimen is increasingly preferred for convenience.
Supporting Evidence
Early treatment data: A 2021 study demonstrated rituximab's effectiveness when used early in AChR antibody-positive generalized MG and impending myasthenic crisis 5. Four of 5 patients with impending myasthenic crisis improved with rituximab alone, with significant QMG score improvements (P < 0.0001).
Long-term outcomes: The RINOMAX trial showed sustained benefit at 24 months with lower QMG scores (mean difference: 2.6,95% CI: 0.3-4.9; p = 0.027) and reduced rescue treatment needs 6. However, infection risk remains a concern (12.5% severe infections).
Recent Cochrane review (2025): Found that rituximab probably results in a large reduction in relapse requiring rescue therapy (RR 0.45,95% CI 0.26-0.78; moderate-certainty evidence), though effects on symptom severity remain uncertain due to limited data 7.
Critical Considerations
Mechanism and Timeline
Rituximab depletes CD20+ B cells within 2 weeks of first infusion 2. B-cell depletion persists for at least 6 months in most patients, with recovery beginning around 6-12 months 2. This delayed onset means rituximab is NOT appropriate for rapid disease control in acute crisis - it serves as rescue therapy for refractory cases or to prevent future crises.
Safety Monitoring
Pre-treatment screening required:
- Baseline immunoglobulin levels (IgG, IgM, IgA)
- Hepatitis B and C antibody levels
- Screen for latent tuberculosis 8
Serious risks to discuss:
- Severe infections (12.5-18.8% in MG studies) 6
- Progressive multifocal leukoencephalopathy (rare but fatal) 8, 3
- Hypogammaglobulinemia with repeated courses 9, 2
- Infusion reactions (20% incidence) 9
Antibody Status Matters
Anti-MuSK positive patients experience greater benefits than AChR-positive or double-seronegative patients 10. However, rituximab remains effective across serotypes for refractory disease.
Common Pitfalls
Using rituximab as first-line in crisis: The guideline is explicit - IVIG or plasmapheresis come first 1. Rituximab's delayed onset makes it unsuitable for immediate crisis management.
Inadequate monitoring: ICU-level monitoring is required for Grade 3-4 MG, with frequent pulmonary function assessment (NIF and VC) and daily neurologic review 1.
Medication interactions: Stop medications that worsen myasthenia: beta-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolide antibiotics 1.
Premature steroid taper: Corticosteroids should continue with taper beginning 3-4 weeks after initiation, based on symptom improvement 1.
Context: Not FDA-Approved for MG
Rituximab is FDA-approved for NHL, CLL, rheumatoid arthritis, GPA, and MPA 2 - but NOT for myasthenia gravis. Its use in MG is off-label, based on guideline recommendations and emerging evidence from autoimmune disease management.